8 April 2021 - The Department of Health and Social Care has asked NICE to produce guidance on using nivolumab with ipilimumab and chemotherapy in the NHS in England.

Nivolumab plus ipilimumab and 2 cycles of platinum-based chemotherapy is not recommended, within its marketing authorisation, for untreated metastatic non-small-cell lung cancer in adults whose tumours have no epidermal growth factor receptor or anaplastic lymphoma kinase mutations.

In the economic model it is uncertain how long the effect of nivolumab combination lasts. It is also unclear whether people having it live longer depending on their PD-L1 TPS and the type of non-small cell lung cancer they have.

Read NICE appraisal consultation document